Endocannabinoid signaling in brain diseases: Emerging relevance of glial cells
dc.contributor.author | Bernal Chico, Ana ![]() | |
dc.contributor.author | Tepavcevic, Vanja | |
dc.contributor.author | Manterola Juaristi, Andrea | |
dc.contributor.author | Utrilla, Carmen | |
dc.contributor.author | Matute Almau, Carlos José | |
dc.contributor.author | Mato Santos, Susana ![]() | |
dc.date.accessioned | 2023-02-09T17:18:29Z | |
dc.date.available | 2023-02-09T17:18:29Z | |
dc.date.issued | 2023-01 | |
dc.identifier.citation | GLIA 71(1) : 103-126 (2023) | es_ES |
dc.identifier.issn | 0894-1491 | |
dc.identifier.issn | 1098-1136 | |
dc.identifier.uri | http://hdl.handle.net/10810/59745 | |
dc.description.abstract | The discovery of cannabinoid receptors as the primary molecular targets of psychotropic cannabinoid Delta(9)-tetrahydrocannabinol (Delta(9)-THC) in late 1980s paved the way for investigations on the effects of cannabis-based therapeutics in brain pathology. Ever since, a wealth of results obtained from studies on human tissue samples and animal models have highlighted a promising therapeutic potential of cannabinoids and endocannabinoids in a variety of neurological disorders. However, clinical success has been limited and major questions concerning endocannabinoid signaling need to be satisfactorily addressed, particularly with regard to their role as modulators of glial cells in neurodegenerative diseases. Indeed, recent studies have brought into the limelight diverse, often unexpected functions of astrocytes, oligodendrocytes, and microglia in brain injury and disease, thus providing scientific basis for targeting glial cells to treat brain disorders. This Review summarizes the current knowledge on the molecular and cellular hallmarks of endocannabinoid signaling in glial cells and its clinical relevance in neurodegenerative and chronic inflammatory disorders. | es_ES |
dc.description.sponsorship | CIBERNED, Grant/Award Number: CB06/05/0076; ARSEP Foundation; European Regional Development Fund (FEDER) and Instituto de Salud Carlos III (ISCIII), Grant/Award Number: PI18/00513; Basque Government, Grant/Award Numbers: PIBA19-0059, IT1203-19; Spanish Ministry of Science and Innovation, Grant/Award Number: SAF2016-75292-R | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Wiley | es_ES |
dc.relation | info:eu-repo/grantAgreement/MINECO/SAF2016-75292-R | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.subject | CB1 | es_ES |
dc.subject | CB2 | es_ES |
dc.subject | endocannabinoids | es_ES |
dc.subject | glial cells | es_ES |
dc.subject | neurodegenerative diseases | es_ES |
dc.title | Endocannabinoid signaling in brain diseases: Emerging relevance of glial cells | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | © 2022 The Authors. GLIA published by Wiley Periodicals LLC. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. | es_ES |
dc.rights.holder | Atribución-NoComercial-SinDerivadas 3.0 España | * |
dc.relation.publisherversion | https://onlinelibrary.wiley.com/doi/10.1002/glia.24172 | es_ES |
dc.identifier.doi | 10.1002/glia.24172 | |
dc.departamentoes | Neurociencias | es_ES |
dc.departamentoeu | Neurozientziak | es_ES |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as © 2022 The Authors. GLIA published by Wiley Periodicals LLC.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.